A Multicenter, Randomized, Comparative Study to Determine the Appropriate Dose of Lansoprazole for Use in the Diagnostic Test for Gastroesophageal Reflux Disease
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The diagnostic proton pump inhibitor test (PPI test) is a method used in diagnosing gastroesophageal reflux disease (GERD). This study aimed to determine the appropriate dose of lansoprazole for use in the diagnostic test for GERD. Methods: This study was a randomized, controlled, multicenter trial in the Daegu-Gyeongbuk area. Patients with typical reflux symptoms such as regurgitation and heartburn for at least three months were enrolled in this study. Patients were divided into two groups, the erosive reflux disease (ERD) group and the non-erosive reflux disease (NERD) group, and randomized to 14 days of treatment with lansoprazole at a dose of 15 mg, 30 mg or 60 mg once daily. The PPI test was considered positive if the patient’s symptoms improved by more than 50%. Results: A total of 218 patients were enrolled, and analysis was performed on the 188 patients who completed the study. The PPI test was positive in 93.2% of the ERD group and 87.2% of the NERD group. A positive PPI test was observed in 91.7%, 89.4%, and 87.2% of the 15 mg, 30 mg, and 60 mg groups, respectively. Significant symptom score changes were observed starting on day 8 for the 15 mg, 30 mg, and 60 mg groups. Conclusions: In this multicenter, randomized study of Korean patients, the standard dose of lansoprazole was as effective as a high dose of lansoprazole in relieving the symptoms of GERD, regardless of the presence of ERD, by day 14 of treatment.
Abstract
Background/Aims: The diagnostic proton pump inhibitor test (PPI test) is a method used in diagnosing gastroesophageal reflux disease (GERD). This study aimed to determine the appropriate dose of lansoprazole for use in the diagnostic test for GERD. Methods: This study was a randomized, controlled, multicenter trial in the Daegu-Gyeongbuk area. Patients with typical reflux symptoms such as regurgitation and heartburn for at least three months were enrolled in this study. Patients were divided into two groups, the erosive reflux disease (ERD) group and the non-erosive reflux disease (NERD) group, and randomized to 14 days of treatment with lansoprazole at a dose of 15 mg, 30 mg or 60 mg once daily. The PPI test was considered positive if the patient’s symptoms improved by more than 50%. Results: A total of 218 patients were enrolled, and analysis was performed on the 188 patients who completed the study. The PPI test was positive in 93.2% of the ERD group and 87.2% of the NERD group. A positive PPI test was observed in 91.7%, 89.4%, and 87.2% of the 15 mg, 30 mg, and 60 mg groups, respectively. Significant symptom score changes were observed starting on day 8 for the 15 mg, 30 mg, and 60 mg groups. Conclusions: In this multicenter, randomized study of Korean patients, the standard dose of lansoprazole was as effective as a high dose of lansoprazole in relieving the symptoms of GERD, regardless of the presence of ERD, by day 14 of treatment.
참고문헌 (16)
- Vakil N, "Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus", Am J Gastroenterol, 101, pp.1900~1920 (2006)
- Richter JE, "The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment", Gastroenterol Clin North Am, 36, pp.577~599 (2007)
- Schenk BE, "Omeprazole as a diagnostic tool in gastroesophageal reflux disease", Am J Gastroenterol, 92, pp.1997~2000 (1997)
- Fass R, "Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease", Arch Intern Med, 159, pp.2161~2168 (1999)
- Schindlbeck NE, "Empiric therapy for gastroesophageal reflux disease", Arch Intern Med, 155, pp.1808~1812 (1995)
- Johnsson F, "One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease", Scand J Gastroenterol, 33, pp.15~20 (1998)
- Johnsson F, "One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease", Scand J Gastroenterol, 38, pp.354~359 (2003)
- Juul-Hansen P, "High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients", Scand J Gastroenterol, 36, pp.806~810 (2001)
- DeVault KR, "Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease", Am J Gastroenterol, 100, pp.190~200 (2005)
- Dent J, "Epidemiology of gastro-oesophageal reflux disease: a systematic review", Gut, 54, pp.710~717 (2005)
- Wong WM, "Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study", Aliment Pharmacol Ther, 18, pp.595~604 (2003)
- Kim N, "The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea", Aliment Pharmacol Ther, 27, pp.173~185 (2008)
- Cho YS, "Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea", Am J Gastroenterol, 100, pp.747~753 (2005)
- Fass R, "The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis", Aliment Pharmacol Ther, 14, pp.389~396 (2000)
- Bruley des Varannes S, "Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers", Aliment Pharmacol Ther, 8, pp.309~314 (1994)
- des Varannes SB, "Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting", World J Gastroenterol, 12, pp.2569~2573 (2006)